ACH Accendra Health Inc.

$ACH Quick backstory for anyone not tracking this one. Accendra is the old Owens & Minor, now a pure-play home-based care business (Apria, Byram) after selling the products segment at the end of 2025. In Aug, a Q2 miss, a guidance reset and a CEO retirement announcement gapped the stock from roughly $3 to under $1.50. It has bled nearly every session since and closed today at $0.22. That said, I initiated a 20K share starter at $0.21. Tell of the tape... technicals I'm looking at • Daily RSI 11.20. Slow Stochastics 3.10 / 3.41. About as stretched as a daily chart gets. • ADX 66 with -DI at 45 and +DI at 4. This has been a one-way trend, not a choppy one. The tell I want is ADX rolling over. • 4.78M shares traded today, roughly 3x the average. Capitulation volume tends to look like this. Why there's a trade here, IMO • Market cap is about $17M against roughly $1.71B of net debt. The equity is a ~1% sliver of enterprise value, so small changes in how the market values the business move the stock in multiples. • No near-term maturity wall. The Jun debt exchange pushed the secured notes out to 2032 and 2033. • $300M revolver was undrawn at quarter-end, with ~$271M available after letters of credit. • Management floated an ATM in Aug, then pulled it. • BofA's latest 13G shows 8.27M shares, 10.8% of the class as of 9/30, up from 3.78M at the end of Q2. • Street targets run $1.30 to $1.75. They're stale, but every one sits above the $1.00 handle. Levels I'm watching • $0.88: the 50-day SMA and the Sept breakdown shelf. A clean 4x from here. The 50-day is falling fast, so a first test likely comes in lower. I'll take it. • $0.195: where market cap crosses $15M. NYSE suspends on a 30-day avg below that, with no cure period. That's the real clock on this name, IMO... more than the $1.00 notice, which carries a 6 mo cure from Oct 6. • Q3 print: not yet confirmed, expected late Oct to early Nov. Bottom line: Again, it's just a spec mean-reversion flyer... and sized as one. 20K shares leaves plenty of room to add on intraday flushes or confirmation of a turn, and the market-cap line above is exactly why I'm not swinging bigger out of the gate. When these washed-out, heavily traded small caps finally turn, the trip back to the 50-day doesn't take long. Anyway, stay tuned. I'll provide an update at some point. As always, just sharing my work. Check everything yourself. Not financial advice.

$ACH on my last post i predicted this was going to 0.50 / if it does not hold the .50's it will go down to the 0.30s / DO NOT touch this stock unless you want to lose your money. They will have to do a reverse split soon to be good with NYSE guidelines. Once they do, the stock price will dropped massively again and back to < $1.00 BK is the only way out of this mess.....

$ACH On February 26, 2025, ACH Board of Directors authorized a share repurchase program of up to $100 million through February 2027. ACH repurchased no shares during H1 2026 but $10M of shares at average price of $5.19 in 2025. $10M represent 40% of shares outstanding that would boost eps by 250% at today's market cap. This is just so ridiculous. I don't think the management will put cash into share repurchase. ACH June 30 Form 10-Q states that the company may repurchase debt through: Open-market purchases Privately negotiated repurchases Tender or exchange offers Contractual repayments or redemptions At 60 cents, $30M could retire $50M of face value debt. So, extreme low equity share price and its debt market value could actually help the company turn around. I truly hope the market price goes even lower.

$ACH It just broke the 30's now..... i mean, how low can this go?? There is no miracle coming to rescue this. They have to reverse split. And then the price will come down some more... way more. DO NOT invest here!

$ACH it just broke the 0.20s, single 0.0X digits are coming in the next few days... this company MC is less then $17MILL.... what a freaking shame! Where is the BOD?

$ACH wow, they pound it hard. The co would definitely need a 500M refinincing or debt for equity swap, as that interest rate expense is way too high, but nothing changed in the last month besides short sellers pounding it to death.

$ACH this thing is so cheap. Would be nice to see some BOD members purchase the stock to show some confidence in the company. The poison pill limits any activist investors taking a position and most of the institutions are stuck at their 4.9% ownership limit to avoid triggering the tax issue with that poison pill they put into place

$ACH The new CEO-transition filing today deserves scrutiny. Ed Pesicka leaves as CEO and director on Oct. 5 but remains an advisor through March 31, 2029. There is no new salary or board authority, but his existing equity awards continue vesting. The nearly 30-month term is long, the required services are broadly defined, and the agreement does not state a conventional no-cause termination right for Accendra. His 2025 LTI grant had an $8.3M grant-date value, although the current value of the remaining awards is not disclosed and performance conditions still apply. Accendra receives transition support, a release and extended restrictive covenants. Still, this appears partly designed to preserve the departing CEO’s equity—not merely facilitate a short handoff. Our read: **negative for governance.

$ACH ACH sold its Products & Healthcare Services (P&HS) operation to Platinum Equity in December 2025 but retained a minority interest. The original transaction agreement specifies an unusual distribution arrangement: 1. The buyer's holding company first makes $310M of aggregate distributions. 2. ACH then participates in 50% of subsequent distributions, until ACH has received $200M. 3. Following the priority returns, ACH participates in 5% of further distributions. That means ACH's retained investment has potential upside well beyond its $20M original carrying value.

$ACH warned it received an NYSE notice for non-compliance with the $1.00 price floor and will seek to cure the deficiency.

$ACH the market is clearly stating there is no expected recovery for the common only question is: Will the board bite the bullet and prepare a prepack filing before the year is up? or will they string this out into next year q1/q2

$ACH - It's hard to imagine this not pushing back up at least a little bit. Continuous red into steep territory can't go on forever. Especially with earnings at the end of this month. Company is still working on restructuring (showing progress last quarter). So definitely not worth zero yet.